Strategies to improve tolerability of rivastigmine: a case series

ABSTRACT Cholinesterase inhibitors, which act by inhibiting the degradation of acetylcholine in the brain, form the mainstay of therapy for AD. Predominant adverse events are cholinergic in nature, the most frequent being gastrointestinal side effects. Here we present a case series of patients with...

Full description

Saved in:
Bibliographic Details
Published in:Current medical research and opinion 2007-01, Vol.23 (1), p.93-95
Main Authors: Venkatesh, K., Bullock, R., Akbas¸, A.
Format: Article
Language:English
Subjects:
Aged
Aged, 80 and over
Alzheimer Disease - drug therapy
Cholinesterase inhibitor
Cholinesterase Inhibitors - adverse effects
Dementia
Female
Gastrointestinal Diseases - etiology
Gastrointestinal Diseases - prevention & control
Humans
Male
Middle Aged
Phenylcarbamates - adverse effects
Rivastigmine
Titration
Tolerability
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c469t-b6b4352edc44d743ef08596ba9e68ba25680b55443ff07351fe4f2d650ec4a453
cites cdi_FETCH-LOGICAL-c469t-b6b4352edc44d743ef08596ba9e68ba25680b55443ff07351fe4f2d650ec4a453
container_end_page 95
container_issue 1
container_start_page 93
container_title Current medical research and opinion
container_volume 23
creator Venkatesh, K.
Bullock, R.
Akbas¸, A.
description ABSTRACT Cholinesterase inhibitors, which act by inhibiting the degradation of acetylcholine in the brain, form the mainstay of therapy for AD. Predominant adverse events are cholinergic in nature, the most frequent being gastrointestinal side effects. Here we present a case series of patients with dementia who were treated with non-standard titration regimens of oral rivastigmine in order to achieve improved tolerability.
doi_str_mv 10.1185/030079906X162791
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1185_030079906X162791</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1230274441</sourcerecordid><originalsourceid>FETCH-LOGICAL-c469t-b6b4352edc44d743ef08596ba9e68ba25680b55443ff07351fe4f2d650ec4a453</originalsourceid><addsrcrecordid>eNp9kM1LAzEQxYMotlbvnmTxvppsks2mnkrxCwoeVPC2ZHcnbcpuU5O00v_elBaKgp5mYN7vzeMhdEnwDSEFv8UUYyElzj9InglJjlCfMEFTVghxjPrbcxrvvIfOvJ9jTLJCylPUIyLjggncR6PX4FSAqQGfBJuYbunsGuLaglOVaU3YJFYnzqyVD2bamQUME5XUykPiwUXsHJ1o1Xq42M8Ben-4fxs_pZOXx-fxaJLWLJchrfKKUZ5BUzPWCEZB44LLvFIS8qJSGc8LXHHOGNUaC8qJBqazJucYaqYYpwN0vfONCT9X4EM5tyu3iC_LDBexB8ZIFOGdqHbWewe6XDrTKbcpCS63lZW_K4vI1d53VXXQHIB9R1FwtxOYhbauU1_WtU0Z1Ka1Tju1qI0v6T_2wx_0DFQbZrVycMj_J_wN7vuLDg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>208007441</pqid></control><display><type>article</type><title>Strategies to improve tolerability of rivastigmine: a case series</title><source>Taylor and Francis:Jisc Collections:Taylor and Francis Read and Publish Agreement 2024-2025:Medical Collection (Reading list)</source><creator>Venkatesh, K. ; Bullock, R. ; Akbas¸, A.</creator><creatorcontrib>Venkatesh, K. ; Bullock, R. ; Akbas¸, A.</creatorcontrib><description>ABSTRACT Cholinesterase inhibitors, which act by inhibiting the degradation of acetylcholine in the brain, form the mainstay of therapy for AD. Predominant adverse events are cholinergic in nature, the most frequent being gastrointestinal side effects. Here we present a case series of patients with dementia who were treated with non-standard titration regimens of oral rivastigmine in order to achieve improved tolerability.</description><identifier>ISSN: 0300-7995</identifier><identifier>EISSN: 1473-4877</identifier><identifier>DOI: 10.1185/030079906X162791</identifier><identifier>PMID: 17257470</identifier><identifier>CODEN: CMROCX</identifier><language>eng</language><publisher>England: Informa UK Ltd</publisher><subject>Aged ; Aged, 80 and over ; Alzheimer Disease - drug therapy ; Cholinesterase inhibitor ; Cholinesterase Inhibitors - adverse effects ; Dementia ; Female ; Gastrointestinal Diseases - etiology ; Gastrointestinal Diseases - prevention &amp; control ; Humans ; Male ; Middle Aged ; Phenylcarbamates - adverse effects ; Rivastigmine ; Titration ; Tolerability</subject><ispartof>Current medical research and opinion, 2007-01, Vol.23 (1), p.93-95</ispartof><rights>2007 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted 2007</rights><rights>Copyright Librapharm Jan 2007</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c469t-b6b4352edc44d743ef08596ba9e68ba25680b55443ff07351fe4f2d650ec4a453</citedby><cites>FETCH-LOGICAL-c469t-b6b4352edc44d743ef08596ba9e68ba25680b55443ff07351fe4f2d650ec4a453</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17257470$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Venkatesh, K.</creatorcontrib><creatorcontrib>Bullock, R.</creatorcontrib><creatorcontrib>Akbas¸, A.</creatorcontrib><title>Strategies to improve tolerability of rivastigmine: a case series</title><title>Current medical research and opinion</title><addtitle>Curr Med Res Opin</addtitle><description>ABSTRACT Cholinesterase inhibitors, which act by inhibiting the degradation of acetylcholine in the brain, form the mainstay of therapy for AD. Predominant adverse events are cholinergic in nature, the most frequent being gastrointestinal side effects. Here we present a case series of patients with dementia who were treated with non-standard titration regimens of oral rivastigmine in order to achieve improved tolerability.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Alzheimer Disease - drug therapy</subject><subject>Cholinesterase inhibitor</subject><subject>Cholinesterase Inhibitors - adverse effects</subject><subject>Dementia</subject><subject>Female</subject><subject>Gastrointestinal Diseases - etiology</subject><subject>Gastrointestinal Diseases - prevention &amp; control</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Phenylcarbamates - adverse effects</subject><subject>Rivastigmine</subject><subject>Titration</subject><subject>Tolerability</subject><issn>0300-7995</issn><issn>1473-4877</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><recordid>eNp9kM1LAzEQxYMotlbvnmTxvppsks2mnkrxCwoeVPC2ZHcnbcpuU5O00v_elBaKgp5mYN7vzeMhdEnwDSEFv8UUYyElzj9InglJjlCfMEFTVghxjPrbcxrvvIfOvJ9jTLJCylPUIyLjggncR6PX4FSAqQGfBJuYbunsGuLaglOVaU3YJFYnzqyVD2bamQUME5XUykPiwUXsHJ1o1Xq42M8Ben-4fxs_pZOXx-fxaJLWLJchrfKKUZ5BUzPWCEZB44LLvFIS8qJSGc8LXHHOGNUaC8qJBqazJucYaqYYpwN0vfONCT9X4EM5tyu3iC_LDBexB8ZIFOGdqHbWewe6XDrTKbcpCS63lZW_K4vI1d53VXXQHIB9R1FwtxOYhbauU1_WtU0Z1Ka1Tju1qI0v6T_2wx_0DFQbZrVycMj_J_wN7vuLDg</recordid><startdate>200701</startdate><enddate>200701</enddate><creator>Venkatesh, K.</creator><creator>Bullock, R.</creator><creator>Akbas¸, A.</creator><general>Informa UK Ltd</general><general>Taylor &amp; Francis</general><general>Informa Healthcare</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>S0X</scope></search><sort><creationdate>200701</creationdate><title>Strategies to improve tolerability of rivastigmine: a case series</title><author>Venkatesh, K. ; Bullock, R. ; Akbas¸, A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c469t-b6b4352edc44d743ef08596ba9e68ba25680b55443ff07351fe4f2d650ec4a453</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Alzheimer Disease - drug therapy</topic><topic>Cholinesterase inhibitor</topic><topic>Cholinesterase Inhibitors - adverse effects</topic><topic>Dementia</topic><topic>Female</topic><topic>Gastrointestinal Diseases - etiology</topic><topic>Gastrointestinal Diseases - prevention &amp; control</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Phenylcarbamates - adverse effects</topic><topic>Rivastigmine</topic><topic>Titration</topic><topic>Tolerability</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Venkatesh, K.</creatorcontrib><creatorcontrib>Bullock, R.</creatorcontrib><creatorcontrib>Akbas¸, A.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>SIRS Editorial</collection><jtitle>Current medical research and opinion</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Venkatesh, K.</au><au>Bullock, R.</au><au>Akbas¸, A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Strategies to improve tolerability of rivastigmine: a case series</atitle><jtitle>Current medical research and opinion</jtitle><addtitle>Curr Med Res Opin</addtitle><date>2007-01</date><risdate>2007</risdate><volume>23</volume><issue>1</issue><spage>93</spage><epage>95</epage><pages>93-95</pages><issn>0300-7995</issn><eissn>1473-4877</eissn><coden>CMROCX</coden><abstract>ABSTRACT Cholinesterase inhibitors, which act by inhibiting the degradation of acetylcholine in the brain, form the mainstay of therapy for AD. Predominant adverse events are cholinergic in nature, the most frequent being gastrointestinal side effects. Here we present a case series of patients with dementia who were treated with non-standard titration regimens of oral rivastigmine in order to achieve improved tolerability.</abstract><cop>England</cop><pub>Informa UK Ltd</pub><pmid>17257470</pmid><doi>10.1185/030079906X162791</doi><tpages>3</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0300-7995
ispartof Current medical research and opinion, 2007-01, Vol.23 (1), p.93-95
issn 0300-7995
1473-4877
language eng
recordid cdi_crossref_primary_10_1185_030079906X162791
source Taylor and Francis:Jisc Collections:Taylor and Francis Read and Publish Agreement 2024-2025:Medical Collection (Reading list)
subjects Aged
Aged, 80 and over
Alzheimer Disease - drug therapy
Cholinesterase inhibitor
Cholinesterase Inhibitors - adverse effects
Dementia
Female
Gastrointestinal Diseases - etiology
Gastrointestinal Diseases - prevention & control
Humans
Male
Middle Aged
Phenylcarbamates - adverse effects
Rivastigmine
Titration
Tolerability
title Strategies to improve tolerability of rivastigmine: a case series
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T21%3A24%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Strategies%20to%20improve%20tolerability%20of%20rivastigmine:%20a%20case%20series&rft.jtitle=Current%20medical%20research%20and%20opinion&rft.au=Venkatesh,%20K.&rft.date=2007-01&rft.volume=23&rft.issue=1&rft.spage=93&rft.epage=95&rft.pages=93-95&rft.issn=0300-7995&rft.eissn=1473-4877&rft.coden=CMROCX&rft_id=info:doi/10.1185/030079906X162791&rft_dat=%3Cproquest_cross%3E1230274441%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c469t-b6b4352edc44d743ef08596ba9e68ba25680b55443ff07351fe4f2d650ec4a453%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=208007441&rft_id=info:pmid/17257470&rfr_iscdi=true